A$11m Financing Facility to Complete Strategic Acquisition
Filed with ASX · · 3 pages · English
Story so far
Earlier from Argent Biopharma
- Quarterly Activities/Appendix 4C Cash Flow Report
- Appendix 4E and 2025 Annual Report
- Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition
- U.S. In Vivo Study Supports ArtemiC Efficacy
- RGT Signs Binding Term Sheet to Acquire AusCann Assets
Later from Argent Biopharma
- Streamlined Acquisition of AusCann Assets
- CannEpil - Largest Commercial Shipment Arrives in Ireland
- Provisional Patent Lodged with USPTO for NanoBodies Platform
- Half Yearly Report and Accounts
- RGT Executes Global CannEpil Licensing Deal for US$5.5M
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma